Clin Res Cardiol: Heterogeneity of prognosis in patients with diabetes mellitus complicated with atrial fibrillation taking edoxaban

Background: In patients with atrial fibrillation (AF) who did not receive oral anticoagulation therapy (OAC), the presence of diabetes mellitus was associated with a higher incidence of thromboembolic events during follow-up, independent of other variables
that affect cardiovascular risk.

Recent studies of patients with atrial fibrillation have explored possible differences
in prognosis in different people with diabetes.

In addition, a recent sub-analysis of anticoagulant patients with atrial fibrillation and diabetes showed an increased cardiovascular risk, mainly associated with myocardial infarction (MI) and cardiovascular death, mainly limited to diabetes
that requires insulin.

Until now, in practical clinical practice associated with patients with atrial fibrillation receiving non-vitamin K antagonists (NOACs), there have been no data
on the predictive effect of various diabetic states (insulin diabetes versus diabetes versus diabetes rather than insulin versus non-diabetes) on clinical outcomes.

Purpose: Our aim was to evaluate in a prospective cohort of edoxaban-treated patients registered in the routine clinical practice of patients with atrial fibrillation in Europe (Etna-AF Europe).

Methodology: We obtained data
from individual patients from the expected, multicenter European registry of Etna-AF.

Results: Of the 13,133 patients, 2,885 had diabetes (22.

Table 1 Coarse incidence of adverse events during two-year follow-up

Figure 1 Kaplan-Meier curve
for survival without ischemic stroke/transient ischemic attack/no SE over two years, depending on the status of diabetes.

Figure 2 Kaplan-Meier curve
for myocardial infarction survival rate based on diabetic state.

Figure 3 The Kaplan-Meier curve shows that diabetics survive
without bleeding over 2 years.

Figure 4 Kaplan-Meier curve
of two-year survival rates based on diabetes status.

Conclusion: In the real cohort of patients taking edoxaban atrial fibrillation, diabetes requiring insulin therapy appears to be an independent factor
influencing the occurrence of thromboembolic events during follow-up.

Original source:

Patti G, Pecen L, Casalnuovo G,Heterogeneity of outcomes within diabetic patients with atrial fibrillation on edoxaban: a sub-analysis from the ETNA-AF Europe registry.